Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature.
The emergence of temozolomide as an effective alkylating agent with little acute toxicity or cumulative myelosuppression has led to protracted courses of chemotherapy for many patients with gliomas. Secondary, or treatment-related, myelodysplasia (t-MDS) and acute myelogenous leukemia (t-AML) are life-threatening complications of alkylating chemotherapy and have been reported in patients with primary brain tumors. We describe a case of temozolomide-related t-MDS/AML and discuss the clinical features of this condition. Administration of an alkylating agent in patient populations with long median survivals must be undertaken with an understanding of the potential for this treatment complication.
Noronha
Vanita
V
Division of Medical Oncology, Department of Medicine, Yale University School of Medicine, New Haven, CT 06510, USA.
Berliner
Nancy
N
Ballen
Karen K
KK
Lacy
Jill
J
Kracher
Jean
J
Baehring
Joachim
J
Henson
John W
JW
D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy*; D003606:Dacarbazine / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced / Q000188:drug therapy*; D009190:Myelodysplastic Syndromes / Q000139:chemically induced / Q000188:drug therapy*; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000188:drug therapy*; D009837:Oligodendroglioma / Q000188:drug therapy*; D000077204:Temozolomide
D003606:Dacarbazine; D000077204:Temozolomide